Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 163 Breast Neoplasms 123 Lung Neoplasms 102 Carcinoma, Non-Small-Cell Lung 84 Glioblastoma 77 Brain Neoplasms 75 Neoplasm Metastasis 68 Glioma 68 Pancreatic Neoplasms 51 Neoplasms 45 Carcinoma, Renal Cell 45 Multiple Myeloma 44 Colorectal Neoplasms 44 Squamous Cell Carcinoma of Head and Neck 39 Lymphoma, Large B-Cell, Diffuse 39 Carcinoma, Hepatocellular 36 Melanoma 35 Ovarian Neoplasms 34 Lymphoma 34 Urinary Bladder Neoplasms 33 Astrocytoma 30 Sarcoma 26 Rectal Neoplasms 26 Uterine Cervical Neoplasms 24 Oropharyngeal Neoplasms 24 Lymphoma, Follicular 24 Central Nervous System Neoplasms 24 Lymphoma, Non-Hodgkin 23 Triple Negative Breast Neoplasms 22 Gliosarcoma 22

Interventions

Carboplatin 12 Pemetrexed 8 pembrolizumab 4 Paclitaxel 4 Cisplatin 4 durvalumab 3 Radiosurgery 3 Gemcitabine 3 selpercatinib 2 pralsetinib 2 osimertinib 2 camrelizumab 2 atezolizumab 2 Docetaxel 2 taletrectinib 1 repotrectinib 1 motexafin gadolinium 1 exemestane 1 entinostat 1 ceralasertib 1 cemiplimab 1 belinostat 1 belagenpumatucel L 1 alectinib 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 TNFSF10 protein, human 1 Radiotherapy 1 Platinum Compounds 1 Patient Reported Outcome Measures 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Bronchogenic × Magnetic Resonance Spectroscopy × Clear all

NCT00652769 2017-11-01

BOOST

University College London Hospitals

Phase 3 Completed

Carcinoma, Bronchogenic, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡